GET DAILY SIGNALSEntrada Therapeutics (TRDA) Q3 2026 Earnings: Narrower Loss Highlights Clinical Momentum
Key Takeaways
- Entrada Therapeutics reported third quarter 2026 collaboration revenue of $0.9 million, down from $1.6 million in the same period a year earlier.
- Net loss narrowed to $39.7 million from $44.1 million, while the reported loss of $0.94 per share came in narrower than the $0.99 per share consensus estimate.
- Revenue of $905,000 fell well short of the roughly $5.87 million analysts had expected, reflecting the wind-down of the Vertex research collaboration.
- Research and development (R&D) expenses declined to $32.4 million from $38.4 million, driven by lower preclinical and facility-related costs for Duchenne programs.
- Cash, cash equivalents and marketable securities totaled $193.0 million, which management expects to fund operations into the fourth quarter of 2027.
- Key catalysts remain on track: ELEVATE-44-201 Cohort 1 data are expected by year-end 2026, with Cohort 2 data to follow in the first quarter of 2027.
Earnings Context and Why It Matters
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines for neuromuscular and inherited retinal diseases, with its lead oligonucleotide programs targeting Duchenne muscular dystrophy (DMD). Because the company does not yet generate product revenue, quarterly results are heavily shaped by collaboration income and R&D spending rather than commercial sales. The sharp drop in collaboration revenue reflects the completion of research activities under the company's Vertex agreement, making cash management and clinical execution the central story. For investors, this report matters less for its income-statement numbers and more for what it signals about the pace of pipeline readouts and the durability of the balance sheet heading into a catalyst-rich 2027. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Entrada reported collaboration revenue of $0.9 million for the third quarter of 2026, compared with $1.6 million in the prior-year period. The reported revenue of $905,000 fell well below the roughly $5.87 million consensus, reflecting the continued transition away from the Vertex research collaboration.
R&D expenses declined to $32.4 million from $38.4 million a year earlier, while general and administrative (G&A) expenses were essentially flat at $10.2 million. Net loss narrowed to $39.7 million from $44.1 million in the third quarter of 2025. On a per-share basis, the reported loss of $0.94 was narrower than the $0.99 analysts had projected.
On the balance sheet, cash, cash equivalents and marketable securities stood at $193.0 million as of September 30, 2026, down from $295.7 million at the end of 2025. Management reiterated that this capital is expected to support operations into the fourth quarter of 2027.
Market Reaction and Investor Sentiment
Shares of TRDA traded lower on November 5, 2026, following the release, with the initial move appearing to reflect disappointment over the substantial revenue miss relative to consensus. Because collaboration revenue is now largely winding down, the market's focus has shifted away from top-line figures and toward the clinical story, where sentiment has been more constructive. The October Cohort 1 data from the ELEVATE-45-201 study of ENTR-601-45 marked a third consecutive readout showing encouraging safety and tolerability, supporting the broader thesis that Entrada's Endosomal Escape Vehicle (EEV) platform can deliver oligonucleotides with a favorable profile. Elevated short interest in the name also remains a factor that can amplify price swings around data-driven catalysts.
Forward Outlook and Key Factors to Monitor
The most important near-term catalyst is the ELEVATE-44-201 program. All Cohort 1 participants have completed open-label dosing, with data expected by the end of 2026, and Cohort 2 data are anticipated in the first quarter of 2027. These readouts will be closely watched for safety, tolerability, and any early functional signals in DMD.
Beyond the Duchenne franchise, investors should track the company's expansion into inherited retinal diseases. Entrada announced its first ocular candidate, ENTR-801, for Usher syndrome type 2A (USH2A), and plans to nominate a second ocular clinical candidate by the end of 2026.
On the financial side, the key question is capital efficiency. With $193.0 million in cash expected to last into the fourth quarter of 2027, the pace of R&D spending and the timing of milestones will determine whether additional financing is eventually needed. Continued milestone payments under the Vertex agreement for VX-670 also represent potential non-dilutive upside, though none are guaranteed. I'm watching this closely as the data readouts approach.
Exploring Tickeron’s AI Screener
In my own research process, Tickeron’s AI Screener has become a practical way to filter biotech names like TRDA against peers using technical patterns, fundamentals, and volatility metrics. It helps surface comparable setups quickly when building a watchlist around upcoming catalysts, without replacing deeper fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TRDA's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for TRDA turned positive on October 28, 2026. Looking at past instances where TRDA's MACD turned positive, the stock continued to rise in 47 of 52 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TRDA's RSI Indicator exited the oversold zone, 14 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on TRDA as a result. In 74 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +16.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRDA advanced for three days, in 263 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
TRDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for TRDA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.759) is normal, around the industry mean (2.904). P/E Ratio (-1.149) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (61.350) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. TRDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Do I Need a more Specialized Financial Advisor?
What are the different types of Growth Funds?
How are Treasury Stock (Treasury Shares) typically used on balance sheets?
What Drives the GBP/USD Currency Pair and How Can Traders Navigate Its Dynamics?
Understanding the Broadening Bottom (Bearish) Pattern in Stock Trading
General Information
Industry Biotechnology
Advertisement